Astelin prescription allergy medication — known in the UK as azelastine nasal spray (brand name Rhinolast) — is a second-generation antihistamine used to relieve the symptoms of allergic rhinitis, including sneezing, nasal itching, congestion, and a runny nose. As a prescription-only medicine (POM) regulated by the MHRA, it must be obtained via a GP or authorised prescriber. Acting directly on the nasal mucosa, azelastine offers rapid symptom relief, often within 15 minutes. This article covers how azelastine works, how it is prescribed under NHS guidance, correct administration, side effects, interactions, and available alternatives.
Summary: Astelin (azelastine hydrochloride nasal spray) is a prescription-only second-generation antihistamine used to relieve allergic rhinitis symptoms; in the UK it is available as Rhinolast or generic azelastine, not under the Astelin brand name.
- Azelastine nasal spray is a prescription-only medicine (POM) in the UK, regulated by the MHRA and available as Rhinolast or generic preparations.
- It works by selectively blocking H1 histamine receptors in the nasal mucosa, providing symptomatic relief typically within 15 minutes of administration.
- NICE CKS guidance supports its use as first-line treatment for mild intermittent allergic rhinitis or as add-on therapy when intranasal corticosteroids alone are insufficient.
- The most common side effect is a bitter or unpleasant taste (dysgeusia); drowsiness is uncommon but may impair driving ability, especially if combined with alcohol or CNS depressants.
- It is not established as safe or effective in children under six years of age, and caution is required in pregnancy and breastfeeding.
- Suspected adverse reactions should be reported to the MHRA via the Yellow Card scheme.
Table of Contents
- What Is Astelin and How Does It Treat Allergies?
- How Azelastine Nasal Spray Is Prescribed in the UK
- How to Use Azelastine Nasal Spray Correctly and What to Expect
- Common and Serious Side Effects to Be Aware Of
- Drug Interactions and Who Should Avoid This Medication
- Alternatives Available on NHS Prescription for Allergic Rhinitis
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Is Astelin and How Does It Treat Allergies?
Astelin is the US brand name for azelastine hydrochloride nasal spray, a second-generation antihistamine that blocks H1 receptors in the nasal mucosa to relieve allergic rhinitis symptoms; in the UK it is marketed as Rhinolast or as a generic preparation.
Astelin is a US brand name for azelastine hydrochloride nasal spray, an antihistamine medication used to relieve the symptoms of allergic rhinitis. The Astelin brand is not marketed in the UK; in the UK, azelastine nasal spray is available under brand names such as Rhinolast, or as a generic azelastine preparation. Understanding how this medication works is important for patients and clinicians when considering treatment options for nasal allergy symptoms.
Azelastine belongs to the second-generation antihistamine class and works by selectively blocking H1 histamine receptors in the nasal mucosa. When allergens such as pollen, dust mites, or pet dander trigger an immune response, the body releases histamine, which causes the characteristic symptoms of allergic rhinitis: sneezing, nasal itching, congestion, and a runny nose. Because azelastine is applied directly into the nose, it acts locally at the site of symptoms; systemic absorption is lower than with oral antihistamines, though it is not entirely absent.
In addition to its antihistamine properties, azelastine has demonstrated anti-inflammatory effects in clinical studies, including inhibition of mast cell degranulation and reduction of certain inflammatory mediators. These properties are described in the product's Summary of Product Characteristics (SmPC) and may contribute to its clinical effectiveness. Importantly, however, azelastine provides rapid symptomatic relief — often within 15 minutes of administration — and its effects do not accumulate over time in the same way as intranasal corticosteroids. It is a practical option for both seasonal and perennial allergic rhinitis, particularly when prompt symptom control is needed.
| Side Effect | Frequency | Severity | Management |
|---|---|---|---|
| Bitter or unpleasant taste (dysgeusia) | Very common (>1 in 10) | Mild | Tilt head forward during use; avoid forceful sniffing after spraying |
| Nasal irritation, burning, or dryness | Common (up to 1 in 10) | Mild | Direct spray away from nasal septum; review technique with GP if persistent |
| Nosebleeds (epistaxis) | Common (up to 1 in 10) | Mild | Correct administration technique reduces risk; seek GP review if recurrent or severe |
| Headache | Common (up to 1 in 10) | Mild | Standard analgesia; consult GP if persistent |
| Somnolence (drowsiness) | Uncommon (up to 1 in 100) | Moderate | Avoid alcohol and CNS depressants; caution when driving or operating machinery |
| Sneezing after administration | Common (up to 1 in 10) | Mild | Usually transient; no specific intervention required |
| Hypersensitivity reaction (rash, urticaria, facial swelling, anaphylaxis) | Rare | Potentially severe | Discontinue immediately; seek emergency medical attention; report via MHRA Yellow Card scheme |
How Azelastine Nasal Spray Is Prescribed in the UK
Azelastine nasal spray is a prescription-only medicine in the UK; NICE CKS guidance supports its use for mild intermittent allergic rhinitis or as add-on therapy, with intranasal corticosteroids preferred for persistent or moderate-to-severe disease.
In the UK, azelastine nasal spray is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is not available over the counter, meaning patients must obtain it via a GP, specialist, or other authorised prescriber.
NICE Clinical Knowledge Summary (CKS) guidance on allergic rhinitis recommends a stepwise approach to treatment, broadly aligned with BSACI guidance. Intranasal antihistamines such as azelastine may be considered as first-line treatment for mild intermittent symptoms, or when rapid symptom relief is required. For persistent or moderate-to-severe allergic rhinitis, intranasal corticosteroids are generally preferred as first-line agents. Azelastine may also be considered when first-line treatments have not provided adequate symptom control, or as an add-on for breakthrough symptoms.
Dosing should follow the specific product SmPC. For Rhinolast 0.1% nasal spray, the usual recommended dose is:
-
Children aged 6 to 11 years: one spray into each nostril twice daily
-
Adolescents and adults aged 12 years and over: one spray into each nostril twice daily; in more severe cases, the dose may be increased to two sprays into each nostril twice daily under medical supervision — the maximum recommended dose should not be exceeded
Prescribers should always refer to the current SmPC for the specific product being prescribed, as formulations may differ. Azelastine is not established as safe and effective in children under six years of age.
Prescribers may also consider the combination product Dymista (azelastine hydrochloride 137 micrograms plus fluticasone propionate 50 micrograms per actuation), which is licensed in the UK for the treatment of moderate-to-severe allergic rhinitis in adults and adolescents aged 12 years and over who are not adequately controlled by either azelastine or an intranasal corticosteroid alone. The recommended dose of Dymista is one spray into each nostril twice daily.
Patients seeking an azelastine prescription should discuss their full allergy history, symptom severity, and any previous treatments with their GP. Referral to an NHS allergy clinic or ear, nose and throat (ENT) specialist may be appropriate if symptoms are poorly controlled or if there is diagnostic uncertainty.
How to Use Azelastine Nasal Spray Correctly and What to Expect
Tilt the head slightly forward, direct the spray towards the outer nostril wall, and breathe in gently through the nose; symptom relief typically begins within 15 to 30 minutes of the first dose.
Correct administration technique is essential to ensure that azelastine nasal spray delivers the medication effectively to the nasal mucosa. Patients should follow these steps for optimal use:
-
Blow the nose gently before using the spray to clear the nasal passages.
-
Shake the bottle gently and prime the pump before first use (or after a period of non-use) by spraying into the air until a fine mist appears.
-
Tilt the head slightly forward, insert the nozzle into one nostril, and direct the spray towards the outer wall of the nose — not towards the nasal septum — to reduce the risk of irritation or nosebleeds.
-
Breathe in gently through the nose as you press the pump, then breathe out through the mouth. Avoid sniffing forcefully after spraying, as this can worsen the bitter taste and reduce local deposition.
-
Repeat for the other nostril as directed.
-
Clean the nozzle regularly as described in the patient information leaflet (PIL) to maintain hygiene and prevent blockage.
A bitter or unpleasant taste is a commonly reported experience after using the spray; keeping the head slightly forward during administration and avoiding forceful sniffing afterwards can help minimise this.
Most patients begin to notice symptom relief within 15 to 30 minutes of the first dose. Unlike intranasal corticosteroids, the benefits of azelastine do not build up progressively over days; it provides direct symptomatic relief during allergen exposure. Using the spray consistently at the recommended times during periods of allergen exposure helps maintain symptom control.
If symptoms do not improve after two weeks of consistent use, patients are advised to return to their GP for reassessment. Patients should seek earlier review if symptoms worsen, or if any of the following red-flag features develop: one-sided nasal blockage, recurrent or severe nosebleeds, facial pain or swelling, loss of smell, or general unwellness.
Common and Serious Side Effects to Be Aware Of
The most common side effect is a bitter taste (dysgeusia), affecting more than 1 in 10 users; serious hypersensitivity reactions are rare but require immediate emergency medical attention.
Experiencing these side effects? Our pharmacists can help you navigate them →
Like all medicines, azelastine nasal spray can cause side effects, although not everyone will experience them. The frequencies below are based on the UK SmPC for azelastine nasal spray; patients should refer to the PIL supplied with their specific product for full details.
Very common side effects (affecting more than 1 in 10 users) may include:
- Bitter or unpleasant taste (dysgeusia) — the most frequently reported complaint, often manageable with correct technique
Common side effects (affecting up to 1 in 10 users) may include:
-
Nasal irritation, burning sensation, or dryness within the nostrils
-
Sneezing shortly after administration
-
Headache
-
Nosebleeds (epistaxis) — usually mild; correct technique reduces the risk
Uncommon side effects (affecting up to 1 in 100 users) may include:
- Somnolence (drowsiness) — less pronounced than with first-generation antihistamines, but possible, particularly if azelastine is used alongside alcohol or other medicines that cause drowsiness
Patients should be advised that drowsiness can impair the ability to drive or operate machinery. Although somnolence is uncommon with the nasal formulation, this risk is increased if azelastine is used alongside alcohol or other central nervous system (CNS) depressants. Patients should exercise caution accordingly.
Not sure if this is normal? Chat with one of our pharmacists →
Serious side effects are rare but include hypersensitivity reactions such as rash, urticaria, or facial swelling. Although rare, anaphylaxis has been reported with antihistamine preparations. Patients experiencing difficulty breathing, severe facial swelling, or a widespread rash should seek emergency medical attention immediately.
Long-term use of any intranasal spray warrants periodic review by a clinician to assess nasal mucosal health. Unlike intranasal corticosteroids, azelastine does not carry a significant risk of mucosal atrophy, but regular GP follow-up remains good practice for any patient on ongoing prescription allergy medication.
Reporting side effects: Patients and healthcare professionals are encouraged to report suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.
Drug Interactions and Who Should Avoid This Medication
The main interaction to consider is enhanced sedation when azelastine is combined with alcohol or CNS depressants; it should be avoided in children under six and used with caution in pregnancy and breastfeeding.
Because systemic absorption of azelastine from the nasal route is low, the risk of clinically significant drug interactions is limited. However, patients and clinicians should be aware of the following.
Key interaction to consider:
- Central nervous system (CNS) depressants — including alcohol, benzodiazepines, opioids, and sedating antihistamines — may enhance the sedative effects of azelastine. Patients should be counselled to avoid or minimise alcohol consumption during treatment and to inform their prescriber of any medicines that cause drowsiness.
Note: Interactions described for high-dose oral azelastine (such as with cimetidine) are not considered clinically relevant for the nasal formulation due to the low systemic exposure achieved. Routine cautions regarding renal or hepatic impairment are not listed in the UK nasal azelastine SmPC; patients with significant organ impairment should discuss their full medical history with their prescriber.
Azelastine nasal spray should be used with caution or avoided in the following groups:
-
Children under six years of age — safety and efficacy have not been established in this age group
-
Pregnant or breastfeeding women — there is insufficient evidence to confirm safety; prescribers should conduct a careful risk–benefit assessment and refer to current MHRA guidance and the product SmPC
-
Patients with known hypersensitivity to azelastine or any excipients listed in the product formulation — note that some formulations contain benzalkonium chloride, which may cause nasal irritation in sensitive individuals; patients should check the PIL for their specific product
Patients should always inform their GP or pharmacist of all current medications, including herbal remedies and supplements, before starting azelastine.
Alternatives Available on NHS Prescription for Allergic Rhinitis
Intranasal corticosteroids such as fluticasone or mometasone are the most effective first-line NHS alternatives for persistent allergic rhinitis; oral antihistamines, saline irrigation, and allergen immunotherapy are also available depending on symptom severity.
For patients who are unable to tolerate azelastine, or for whom it is not appropriate, the NHS offers a range of evidence-based alternatives for the management of allergic rhinitis. NICE CKS guidance and BSACI guidelines recommend tailoring treatment to symptom severity, patient preference, and response to previous therapies.
Intranasal corticosteroids are considered the most effective first-line treatment for persistent or moderate-to-severe allergic rhinitis and are widely available on NHS prescription. Options include:
-
Beclometasone dipropionate (e.g., Beconase)
-
Fluticasone propionate (e.g., Flixonase)
-
Mometasone furoate (e.g., Nasonex)
-
Budesonide (e.g., Rhinocort)
These agents reduce nasal inflammation over time and are particularly effective for nasal congestion, though they may take several days to reach full effect.
Oral antihistamines such as cetirizine, loratadine, and fexofenadine are available both over the counter and on prescription. They are particularly useful for patients with predominantly sneezing, itching, and rhinorrhoea, and are often recommended as first-line treatment for mild intermittent symptoms.
Intranasal ipratropium bromide may be considered for patients with prominent watery rhinorrhoea that is not adequately controlled by other treatments.
Saline nasal irrigation (e.g., using a saline rinse or spray) is a safe, non-pharmacological option that can help relieve nasal congestion and clear allergens from the nasal passages; it may be used alongside other treatments.
Sodium cromoglicate nasal spray or eye drops may be useful, particularly for patients with prominent ocular symptoms such as itchy, watery eyes.
For patients with both nasal and ocular symptoms, a combination approach — such as an intranasal corticosteroid alongside an oral antihistamine — may be appropriate. The combination nasal spray Dymista (azelastine plus fluticasone propionate) is also available on NHS prescription for eligible patients aged 12 years and over with moderate-to-severe allergic rhinitis not adequately controlled by either agent alone.
Nasal decongestants (e.g., xylometazoline) may provide short-term relief of congestion but should be used for no more than seven days continuously, as prolonged use can cause rebound congestion (rhinitis medicamentosa).
In cases of severe or refractory allergic rhinitis, referral to an NHS allergy specialist or ENT service should be considered. Referral is particularly appropriate where there is diagnostic uncertainty, suspected nasal polyps, unilateral nasal symptoms, recurrent severe epistaxis, significant impact on asthma control, or where allergen immunotherapy (desensitisation) is being considered. Allergen immunotherapy aims to modify the underlying immune response and can provide long-term symptom relief; it is available through specialist NHS services as per BSACI guidance. Patients should discuss all available options with their GP to determine the most suitable management plan.
Frequently Asked Questions
Is Astelin available on NHS prescription in the UK?
The Astelin brand is not marketed in the UK, but azelastine hydrochloride nasal spray — the same active ingredient — is available on NHS prescription under the brand name Rhinolast or as a generic preparation, and must be prescribed by a GP or authorised prescriber.
How quickly does azelastine nasal spray work for allergic rhinitis?
Azelastine nasal spray typically begins to relieve allergic rhinitis symptoms within 15 to 30 minutes of administration, making it a useful option when rapid symptom control is needed during allergen exposure.
Can azelastine nasal spray cause drowsiness?
Drowsiness is an uncommon side effect of azelastine nasal spray, but it can impair the ability to drive or operate machinery, particularly if the spray is used alongside alcohol or other medicines that cause sedation.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
